Thomas Williams

Professor of Haemoglobinopathy Research

Imperial College London

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Thomas Williams is a faculty member in the Department of Haemoglobinopathy Research at Imperial College London, UK. His current research focuses on sickle cell anemia, malaria, and related pharmacological studies, as evidenced by his recent publications. He is particularly interested in global health issues affecting children, including growth patterns in Kenyan children with sickle cell anemia and the efficacy of hydroxyurea treatment in reducing malaria incidence.

Articles (15)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (8)

Reagan Mogire

Open University

UNITED KINGDOM

View details

Roisin Connon

University College London

UNITED KINGDOM

View details

John N. Brewin

UNITED KINGDOM

View details

Kathryn Maitland

Professor Paediatric Tropical Infectious Diseases

Imperial College London

UNITED KINGDOM

View details

David Rees

Professor

King’s College London

UNITED KINGDOM

View details

Jørgen Kurtzhals

Associate dean of education

University of Copenhagen

DENMARK

View details

Julian C Rayner

UNITED KINGDOM

View details

George Tomlinson

University of Toronto

CANADA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Thomas Williams

Research Interests

Explore related searches

Contact this professor

About

Articles (15)

Development of disease-specific growth curves from Kenyan children with sickle cell anemia

Hydroxyurea pharmacokinetics in children with sickle cell anemia across different global populations

SEVUparin as a potential Adjunctive Treatment in children with severe malaria: A phase I trial safety and dose finding trial (SEVUSMAART)

Reducing transfusion utilization for children with sickle cell anemia in sub‐Saharan Africa with hydroxyurea: Analysis from the phase I/II REACH trial

The Dantu blood group prevents parasite growth in vivo: Evidence from a controlled human malaria infection study

Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa

Pharmacokinetics and pharmacodynamics of azithromycin in severe malaria bacterial co-infection in African children (TABS-PKPD): a protocol for a Phase II randomised controlled trial

SEVUparin as a potential Adjunctive Treatment in children with severe malaria: A phase I trial safety and dose finding trial (SEVUSMAART)

The significance of spleen size in children with sickle cell anemia

Case Report: β-thalassemia major on the East African coast

Pharmacokinetics and pharmacodynamics of azithromycin in severe malaria bacterial co-infection in African children (TABS-PKPD): a protocol for a Phase II randomised controlled trial

How Severe Anaemia Might Influence the Risk of Invasive Bacterial Infections in African Children

β‐Thalassemia pathogenic variants in a cohort of children from the East African coast

Effects of vitamin D deficiency on neurobehavioural outcomes in children: a systematic review

Human genetics and malaria resistance

Collaborators (8)

Reagan Mogire

Roisin Connon

John N. Brewin

Kathryn Maitland

David Rees

Jørgen Kurtzhals

Julian C Rayner

George Tomlinson

Make your next move.